ClinicalTrials.gg
RecruitingNCT07219212LUMIRAYUpdated Nov 3, 2026

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 1 interventional study of JNJ-90301900 and Cisplatin in Squamous Cell Carcinoma of Head and Neck, sponsored by Johnson & Johnson Enterprise Innovation Inc.. Recruiting at 25 sites in 4 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Johnson & Johnson Enterprise Innovation Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Updated Nov 3, 2026First site in SpainSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 217 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
457th of 993
45 · median 41
Started
2026
with 59 others
Phase 1
362 of 1,099
71 open now
Primary completion
2028-07
later than 246 of 346 live
Registered
1,048th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 457th largest by planned enrollment of the 993 interventional ones that give a count, is one of 60 that started in 2026, is one of 362 in phase 1, reaches primary completion later than 246 of the 346 other live ones, and was the 1,048th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

217 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

212 more — sign in →

All 217 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).

03

Conditions studied

  • Squamous Cell Carcinoma of Head and Neck
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
  • Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines
  • A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines
  • Participants must have at least 1 target lesion (primary tumor or involved lymph node) per v.1.1
  • Performance Status (ECOG PS) 0 or 1

Exclusion criteria

Exclusion criteria:

  • Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site
  • Non-squamous histology
  • Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months)
  • Ineligible to receive platinum-based chemotherapy
  • Suspected or known allergies, , or intolerance to JNJ-90301900 or its
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    JNJ-90301900 + Concurrent Chemoradiation Therapy (cCRT)

    Participants will receive JNJ-90301900 administered intratumorally and/or intranodally, in combination with concurrent chemoradiation therapy (cCRT) consisting of platinum based chemotherapy (cisplatin or carboplatin/paclitaxel) and intensity-modulated radiation therapy (IMRT). Post-treatment follow-up will continue until the end of study (EOS), radiographic disease progression, study discontinuation, or study completion, whichever occurs first.

    Drug: JNJ-90301900 · Drug: Cisplatin · Radiation: Intensity Modulated Radiation Therapy (IMRT) · Drug: Carboplatin · Drug: Paclitaxel

Interventions

  • JNJ-90301900 will administered via intratumoral and/or intranodal injection.

    Also known as: NBTXR3, Functionalized hafnium oxide nanoparticles

  • Cisplatin will be administered intravenously.

  • RadiationIntensity Modulated Radiation Therapy (IMRT)

    IMRT radiation therapy will be administered.

  • Carboplatin will be administered intravenously.

  • Paclitaxel will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs) by Severity

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0.

    Time frame: Up to approximately 2 years 14 weeks

Secondary outcomes

  1. Complete Response (CR) Rate

    Percentage of participants achieving CR according to RECIST v.1.1 will be reported.

    Time frame: Up to approximately 2 years 14 weeks

  2. Objective Response Rate (ORR) According to RECIST v.1.1

    ORR defined as percentage of participants achieving complete response (CR) or partial response (PR) by investigator assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.

    Time frame: Up to approximately 2 years 14 weeks

  3. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants achieving CR, PR, or stable disease (SD) as per RECIST v.1.1 criteria.

    Time frame: Up to approximately 2 years 14 weeks

  4. Injected Tumor Response Rate

    Response rate will be measured based on total tumor shrinkage compared to baseline among those lesions injected with JNJ-90301900.

    Time frame: Up to approximately 2 years 14 weeks

  5. Time to Locoregional Failure (LRF)

    Time to LRF is defined as time from enrollment to first failure of LRF using investigator RECIST v.1.1 assessments.

    Time frame: Up to approximately 2 years 14 weeks

  6. Time to Distant Failure (DF)

    Time to DF is defined as time from enrollment to first failure of DF using investigator RECIST v.1.1 assessments.

    Time frame: Up to approximately 2 years 14 weeks

  7. Progression Free Survival (PFS)

    PFS is defined as the time from enrollment to radiographic disease progression, or death from any cause, whichever occurs first.

    Time frame: Up to approximately 2 years 14 weeks

  8. Number of Participants with Post-Radiation Neck Dissection (PRND)

    Participants with PRND will be summarized and will continue to be radiographically evaluated for response by RECIST v.1.1.

    Time frame: Up to approximately 2 years 14 weeks

  9. Number of Participants with Post-Radiation Primary Surgery

    Participants with post-radiation primary surgery will be summarized and will continue to be radiographically evaluated for response by RECIST v.1.1.

    Time frame: Up to approximately 2 years 14 weeks

07

Study locations

24 of 25 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 29 months after the start.

Of 154 industry-sponsored phase 1 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 72. This study's planned 29 months is below that.

Counting every sponsor, half of 270 studies reached it within 49 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 21, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Jul 14, 2028
CompletionEst.
Jul 14, 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Spain. University of California at San Diego Moores Cancer Center is now Suspended
Show 6 added (4 Spain, 1 France, 1 Japan)
  • CHU de Grenoble · La Tronche, France
  • National Cancer Center Hospital East · Kashiwa, Japan
  • ICO L'Hospitalet - Hospital Duran i Reynals · Barcelona, Spain
  • Hosp. Gral. Univ. Gregorio Maranon · Madrid, Spain
  • Hosp Univ Fund Jimenez Diaz · Madrid, Spain
  • Hosp. Univ. I Politecni La Fe · Valencia, Spain
across 2 updates, Sep 25, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    5 sites added — first site in Spain
    Show 5 added (4 Spain, 1 Japan)
    • National Cancer Center Hospital East · Kashiwa, Japan
    • ICO L'Hospitalet - Hospital Duran i Reynals · Barcelona, Spain
    • Hosp. Gral. Univ. Gregorio Maranon · Madrid, Spain
    • Hosp Univ Fund Jimenez Diaz · Madrid, Spain
    • Hosp. Univ. I Politecni La Fe · Valencia, Spain
    + 1 other change: verification date
  2. Sep 25, 2026
    1 site added. University of California at San Diego Moores Cancer Center is now Suspended
    Show site
    • CHU de Grenoble · La Tronche, France
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07219212
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Jan 26, 2026
Primary completion
Jul 14, 2028 (estimated)
Completion
Jul 14, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Johnson & Johnson Enterprise Innovation, Inc. Clinical Trial
study director · Johnson & Johnson Enterprise Innovation Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hafnium oxide

Start the discussion